What was the market valuation for hemiplegic migraine in China in 2024?

The market valuation for hemiplegic migraine in China was $0.08 Million in 2024. Read More

What is the projected market valuation for hemiplegic migraine in China by 2035?

The projected market valuation for hemiplegic migraine in China is $0.118 Million by 2035. Read More

What is the expected CAGR for the hemiplegic migraine market in China during the forecast period 2025 - 2035?

The expected CAGR for the hemiplegic migraine market in China during the forecast period 2025 - 2035 is 3.55%. Read More

Which companies are key players in the hemiplegic migraine market in China?

Key players in the hemiplegic migraine market in China include Amgen Inc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Novartis AG, Pfizer Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, and Bristol-Myers Squibb Company. Read More

What are the segment valuations for Familial and Sporadic Hemiplegic Migraine in 2024?

In 2024, the segment valuation for Familial Hemiplegic Migraine was $0.03 Million, while Sporadic Hemiplegic Migraine was valued at $0.05 Million. Read More

What treatment options are available for hemiplegic migraine in China?

Treatment options for hemiplegic migraine in China include Acute treatment, Triptans, Ergotamines, NSAIDs, Antiemetics, Narcotic Analgesics, and others, with varying valuations. Read More

What is the market valuation for preventive treatments like Botox injections in 2024?

The market valuation for preventive treatments, such as Botox injections, was $0.03 Million in 2024. Read More

How do distribution channels for hemiplegic migraine treatments perform in China?

In 2024, distribution channels for hemiplegic migraine treatments included Retail Pharmacies at $0.03 Million and Hospital Pharmacies at $0.025 Million. Read More

What is the valuation for hospitals and clinics as end-users in the hemiplegic migraine market?

The valuation for hospitals and clinics as end-users in the hemiplegic migraine market was $0.032 Million in 2024. Read More

What are the projected trends for the hemiplegic migraine market in China by 2035?

Projected trends for the hemiplegic migraine market in China by 2035 indicate a growth in market valuation to $0.118 Million, reflecting an increasing awareness and treatment options. Read More

China Hemiplegic Migraine Market

China Hemiplegic Migraine Market Research Report By Type (Familial, Sporadic), By Treatment (Acute, Preventive), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and By End-user (Hospitals & Clinics, Diagnostic Centers, Others) -Forecast to 2035

Forecast Period

2025 - 2035

CAGR

3.55%

2024 Market Size

$ 0.08 Million

2035 Market Size

$ 0.12 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/51969-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Type (USD Million)
  1. 4.1.1 Familial Hemiplegic Migraine
  2. 4.1.2 Sporadic Hemiplegic Migraine
2. 4.2 Medical Device, BY Treatment (USD Million)
  1. 4.2.1 Acute treatment
  2. 4.2.2 Triptans
  3. 4.2.3 Ergotamines
  4. 4.2.4 NSAIDs
  5. 4.2.5 Antiemetics
  6. 4.2.6 Narcotic Analgesics
  7. 4.2.7 Others
3. 4.3 Medical Device, BY End-user (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Diagnostic Centers
  3. 4.3.3 Others
4. 4.4 Medical Device, BY Preventive Treatment (USD Million)
  1. 4.4.1 Antidepressants
  2. 4.4.2 Botox Injections
  3. 4.4.3 Others
5. 4.5 Medical Device, BY Distribution Channel (USD Million)
  1. 4.5.1 Retail Pharmacies
  2. 4.5.2 Hospital Pharmacies
  3. 4.5.3 Online Pharmacies
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca PLC (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Boehringer Ingelheim GmbH (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TYPE
3. 6.3 CHINA MARKET ANALYSIS BY TREATMENT
4. 6.4 CHINA MARKET ANALYSIS BY END-USER
5. 6.5 CHINA MARKET ANALYSIS BY PREVENTIVE TREATMENT
6. 6.6 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF MEDICAL DEVICE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF MEDICAL DEVICE
10. 6.10 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
12. 6.12 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
13. 6.13 MEDICAL DEVICE, BY TYPE, 2024 (% SHARE)
14. 6.14 MEDICAL DEVICE, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
16. 6.16 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
17. 6.17 MEDICAL DEVICE, BY END-USER, 2024 (% SHARE)
18. 6.18 MEDICAL DEVICE, BY END-USER, 2024 TO 2035 (USD Million)
19. 6.19 MEDICAL DEVICE, BY PREVENTIVE TREATMENT, 2024 (% SHARE)
20. 6.20 MEDICAL DEVICE, BY PREVENTIVE TREATMENT, 2024 TO 2035 (USD Million)
21. 6.21 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
  4. 7.2.4 BY PREVENTIVE TREATMENT, 2025-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Hemiplegic Migraine Market Segmentation

China Hemiplegic Migraine Market By Type (USD Million, 2025-2035)

Familial Hemiplegic Migraine
Sporadic Hemiplegic Migraine

China Hemiplegic Migraine Market By Treatment (USD Million, 2025-2035)

Acute treatment
Triptans
Ergotamines
NSAIDs
Antiemetics
Narcotic Analgesics
Others

China Hemiplegic Migraine Market By End-user (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Others

China Hemiplegic Migraine Market By Preventive Treatment (USD Million, 2025-2035)

Antidepressants
Botox Injections
Others

China Hemiplegic Migraine Market By Distribution Channel (USD Million, 2025-2035)

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”